相关实验视频

Updated: Jun 7, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

对于未经治疗的EGFR突变性高级NSCLC的EGFR-TKI或EGFR-TKI组合治疗:一个网络元分析

Ao Liu¹, Xiaoming Wang², Lian Wang²

¹Department of Respiratory Medicine, Chengdu BOE Hospital, Chengdu, Sichuan Province, 610000, China. liuaodoc@gmail.com.

|November 13, 2024

概括

对于晚期EGFR突变非小细胞肺癌,奥西默蒂尼布加化学疗法和拉泽蒂尼布加阿米万塔马布是优越的第一线治疗方法. 这些组合改善了无进展的生存率,但增加了不良事件.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

皮表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 是EGFR突变非小细胞肺癌 (NSCLC) 的标准一线治疗方法.
在各种EGFR-TKI单一疗法和组合疗法之间,最佳的第一线治疗选择仍未确定.
本研究提供了对这些治疗方法在先进NSCLC中的疗效和安全性的比较分析.

研究的目的:

为了比较一线EGFR-TKI单一治疗和组合治疗的疗效和安全性.
为了确定高级EGFR突变NSCLC的优质治疗选择.
为第一线治疗的临床决策提供信息.

主要方法:

在PubMed,Embase,Cochrane图书馆和会议记录中进行系统的文献搜索.
包括对EGFR-TKI一线治疗先进EGFR突变NSCLC的随机对照试验.
网络元分析使用频率主义方法来比较疗效和安全性结果,并进行偏差风险评估.

主要成果:

分析了26项涉及14个治疗组的8359名患者的试验.
奥西默蒂尼布加化疗和拉泽蒂尼布加艾米万塔马布在无进展生存方面表现出最高的疗效.
新的第三代EGFR-TKIs的疗效与单独使用 osimertinib 的疗效相当;组合治疗增加了不良事件.

结论:

奥西默蒂尼布加化疗和拉泽蒂尼布加阿米万塔马布被确定为高级EGFR突变NSCLC的优质一线选择.
虽然有效,但这些组合疗法与更高的不良事件发生率有关.
进一步的研究可能会探索优化这些组合以减轻副作用.

关键词:

在前面和后面的朋友.欧洲农业基金-土耳其.拉泽蒂尼布 (Lazertinib) 是一种药物.非小细胞肺癌是非小细胞肺癌.奥西默蒂尼布 (Osimertinib) 是一种药物.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...